Register for our free email digests:
Latest From LipimetiX LLC
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- LipimetiX LLC
- Senior Management
Dennis Goldberg, PhD, Pres. & CEO
Phillip M Friden, PhD, VP, R&D
Randolph C Steer, MD, PhD, CMO
- Contact Info
Phone: (978) 261-5467
50 Lands End Ln.
Sudbury, MA 01776
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.